FDA Approves New TB Drug

Sirturo is the first drug approved to treat multi-drug resistant TB. It works by inhibiting an enzyme needed by M. tuberculosis to replicate and spread throughout the body.

The U.S. Food and Drug Administration announced Dec. 31 it has approved Sirturo (bedaquiline) as part of combination therapy to treat adults with multi-drug resistant pulmonary tuberculosis when alternatives are not available.

TB is an infection caused by Mycobacterium tuberculosis; CDC reports nearly 9 million people around the world and 10,528 people in the United States became sick with TB during 2011. Multi-drug resistant TB occurs when M. tuberculosis becomes resistant to isonazid and rifampin, the drugs most commonly used to treat TB. Sirturo is the first drug approved to treat multi-drug resistant TB and works by inhibiting an enzyme needed by M. tuberculosis to replicate and spread throughout the body.

"Multi-drug resistant tuberculosis poses a serious health threat throughout the world, and Sirturo provides much-needed treatment for patients who have don't have other therapeutic options available," said Edward Cox, M.D., MPH, director of the Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research. "However, because the drug also carries some significant risks, doctors should make sure they use it appropriately and only in patients who don't have other treatment options."

Sirturo is being approved under FDA's accelerated approval program, which allows for earlier access to promising new drugs while the companies conduct additional studies to confirm their clinical benefit and safe use. FDA also granted Sirturo fast track designation, priority review, and orphan-product designation. "The drug demonstrated the potential to fill an unmet medical need, has the potential to provide safe and effective treatment where no satisfactory alternative therapy exists, and is intended to treat a rare disease, respectively," according to the agency's news release.

Sirturo's manufacturer, Janssen Therapeutics, is a division of Janssen Products LP and is based in Titusville, N.J.

Download Center

HTML - No Current Item Deck
  • Safety Management Software - Free Demo

    IndustrySafe Safety Software’s comprehensive suite of modules help organizations to record and manage incidents, inspections, hazards, behavior based safety observations, and much more. Improve safety with an easy to use tool for tracking, notifying and reporting on key safety data.

  • Create Flexible Safety Dashboards

    IndustrySafe’s Dashboard Module allows organizations allows you to easily create and view safety KPIs to help you make informed business decisions. Our best of breed default indicators can also save you valuable time and effort in monitoring safety metrics.

  • Schedule and Record Observations

    IndustrySafe's Observations module allows managers, supervisors, and employees to conduct observations on employees involved in safety critical behavior. IndustrySafe’s pre-built BBS checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Why Is Near Miss Reporting Important?

    A near miss is an accident that's waiting to happen. Learn how to investigate these close calls and prevent more serious incidents from occurring in the future.

  • Get the Ultimate Guide to Safety Training

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We’ve put together a guide on key safety training topics, requirements for certifications, and answers to common FAQs.

  • Industry Safe
comments powered by Disqus

OH&S Digital Edition

  • OHS Magazine Digital Edition - June 2019

    June 2019

    Featuring:

    • ASSP SAFETY 2019 PREVIEW
      New Orleans Networking
    • NATION SAFETY MONTH
      Heed These Summer Safety Tips
    • TRAINING
      Education, Skill Development, and Behavior Change
    • SAFETY MANAGEMENT
      What Good Looks Like
    View This Issue

Bulwark Quiz